Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia

被引:42
作者
Hursting, MJ
Lewis, BE
Macfarlane, DE
机构
[1] Clin Sci Consulting, Potomac, MD 20854 USA
[2] Loyola Univ, Med Ctr, Maywood, IL 60153 USA
[3] Univ Iowa, Iowa City, IA USA
关键词
argatroban; direct thrombin inhibitor; warfarin; oral anticoagulation; heparin induced thrombocytopenia;
D O I
10.1177/107602960501100306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Argatroban, a direct thrombin inhibitor used for thromboprophylaxis or treatment in heparin-induced thrombocytopenia (HIT), is routinely monitored using the activated partial thromboplastin time (aPTT) yet also prolongs the international normalized ratio (INR). Peritransitional INRs, aPTTs, anticoagulant dosing patterns, and outcomes were evaluated in 165 HIT patients who were transitioned, without guidelines, from argatroban to warfarin therapy. Argatroban (median doses: 1.5-2.0 mcg/kg/min) and warfarin (median dose: 5 mg initially with 3.8 mg/day thereafter) overlapped a median 4 days. Median (5-95th percentile) aPTTs (in seconds) and INRs, respectively, were 59.8 (38.8-82.9) and 3.2 (1.7-7.0) during argatroban monotherapy, 68.6 (44.5-104) and 5.3 (2.4-16) maximally during cotherapy, 59.9 (38.7-92.2) and 4.0 (2.2-11.6) immediately before argatroban cessation during cotherapy, and 36.0 (25.6-60.2) and 2.3 (1.3-7.3) within a median 10-12 hours after argatroban cessation. Major bleeding occurred in 1 (0.6%) patient pretransitionally and no patient during or after cotherapy. Eighteen (10.9%) patients experienced 19 peritransitional adverse outcomes (one death, two amputations, 16 new thromboses); these patients had more severe HIT than event-free patients (median baseline platelet count, 39 vs. 83 x 10(9)/L. Of 108 patients with post-transitional INR data, 43 achieved a therapeutic INR (prospectively defined as 1.9-3.5), 34 were subtherapeutic, and 31 were supratherapeutic, with no across-group trend in new thrombosis. Hence in the absence of guidelines, physicians transfer patients from argatroban to warfarin therapy with acceptably low complication rates in HIT, without systematically over- or under-dosing warfarin. Furthermore, INRs greater than 5 commonly occur in HIT patients during argatroban monotherapy and argatroban/warfarin cotherapy, without major bleeding.
引用
收藏
页码:279 / 287
页数:9
相关论文
共 22 条
[1]   Lack of pharmacokinetic interactions between argatroban and warfarin [J].
Brown, PM ;
Hursting, MJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (21) :2078-2083
[2]  
Fairweather RB, 1998, ARCH PATHOL LAB MED, V122, P768
[3]  
Fenyvesi T, 2002, CLIN CHEM, V48, P1791
[4]   Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values [J].
Gosselin, RC ;
Dager, WE ;
King, JH ;
Janatpour, K ;
Mahackian, K ;
Larkin, EC ;
Owings, JT .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (04) :593-599
[5]   Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia -: A prospective study [J].
Greinacher, A ;
Völpel, H ;
Janssens, U ;
Hach-Wunderle, V ;
Kemkes-Matthes, B ;
Eichler, P ;
Mueller-Velten, HG ;
Pötzsch, B .
CIRCULATION, 1999, 99 (01) :73-80
[6]   Transition from argatroban to oral anticoagulation with phenprocournon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time [J].
Harder, S ;
Graff, J ;
Klinkhardt, U ;
von Hentig, N ;
Walenga, JM ;
Watanabe, H ;
Osakabe, M ;
Breddin, HK .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (06) :1137-1145
[7]   American Heart Association/American College of Cardiology Foundation guide to warfarin therapy [J].
Hirsh, J ;
Fuster, V ;
Ansell, J ;
Halperin, JL .
CIRCULATION, 2003, 107 (12) :1692-1711
[8]   Treatment of heparin-induced thrombocytopenia - A critical review [J].
Hirsh, J ;
Heddle, N ;
Kelton, JG .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (04) :361-369
[9]  
Hursting MJ, 1999, CLIN CHEM, V45, P409
[10]  
KELTON JG, 2003, J THROMB HEMOST S1, V1